

## Special Issue

# SARS-CoV-2, COVID-19 Pathologies, Long COVID, and Anti-COVID Vaccines

### Message from the Guest Editor

This Special Issue of the international scientific journal *Viruses* concerns the SARS-CoV-2 virus, the pathologies of COVID-19, and long COVID, as well as anti-COVID vaccines and their potential harmful effects on the human body (in particular, mRNA vaccines). All aspects are covered in this Special Issue, from the mode of action of the virus or the Spike protein, to the adverse effects concerning neurodegeneration, cardiovascular and gastrointestinal disorders, autoimmunity, and cancers. The dysregulation of the renin-angiotensin system and the overactivation of the AT1R receptor by excess angiotensin-2, at the origin of COVID-19 pathologies or long COVID, are included in this Special Issue. Potential drug treatments can be discussed depending on the case.

### Guest Editor

Prof. Dr. Jean-Marc Sabatier

Institute of NeuroPhysiopathology, UMR 7051, Faculté de Médecine  
Secteur Nord, 51, Boulevard Pierre Dramard - CS80011, 13344 -  
Marseille Cedex 15, France

### Deadline for manuscript submissions

closed (31 December 2025)



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/239607](https://mdpi.com/si/239607)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).